In patients with auto-immune conditions who are receiving immunosuppressive therapy of variable efficacy and strength and who experience acute and recurrent pericarditis, the long-term safety of the addition of IL-1 inhibitors remains unclear. The gene discussed is IL1A; the disease is pericarditis.